Price discrimination for pharmaceuticals: Welfare effects in the us and the eu

International Journal of the Economics of Business

Volumn 4, Issue 3, 1997, Pages 301-322

  Danzon, Patricia M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antitrust policy; Jel classifications: l41, l51, l65, 111, k21; Parallel trade; Pharmaceutical industry; Price discrimination; Ramsey pricing; Regulation

Indexed keywords

EID: 84964028597     PISSN: 13571516     EISSN: 14661829     Source Type: Journal    
DOI: 10.1080/758523212     Document Type: Article

References (25)

1. Baumol, W.J., and Bradford, D.F., 1970. “Optimal Departures From Marginal Cost Pricing”. The American Economic Review,: 265–283.
2. Berndt, E., 1994. Uniform Pricing: An Economic Analysis, Washington, D.C: American Enterprise Institute Press.
3. Braeutigam, R.R., 1984. “Socially Optimal Pricing with Rivalry and Economies of Scale”. Rand Journal of Economics,: 127–134.
4. Caves, R.E.J, Whinston, M.D., and Hurwitz, M.A., 1991. “Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry”. Brookings Papers on Economic Activity: Microeconomics,: 1–66.
5. Danzon, P.M., 1997. Trade and Price Differentials for Pharmaceuticals: Policy Options, London: Office of Health Economics.
6. Danzon, P.M., and Kim, J.D., 1995. “International Price Comparisons for Pharmaceuticals”. 1–34. Philadelphia: The Wharton School. Working Paper
7. Danzon, P.M., and Liu, H., 1997. “Reference Pricing And Physician Drug Budgets: The German Experience In Controlling Pharmaceutical Expenditures”. Philadelphia: The Wharton School. Working Paper
8. Danzon, P.M., and Percy, A., 1996. “The Effects of Price Regulation on Productivity in Pharmaceuticals”. 1–31. Philadelphia: The Wharton School. Working Paper
9. DiMasi, J.A., Hansen, R.W., Grabowski, H.G., and Lasagna, L., 1991. “The Cost of Innovation in the Pharmaceutical Industry”. Journal of Health Economics, 10: 107–142.
10. Dranove, D., 1988. “Pricing by Non-Profit Institutions: The Case of Hospital Cost-Shifting”. Journal of, 7: 47–57.
11. Freeh, H.E., III and Rochlin, C.B., “Advertising as a Privately Supplied Public Good”. Economic Enquiry, XVII414–418.
12. Grabowski, H.G., and Vemon, J.H., 1992. “Brand Loyalty, Entry and Price Competition in Pharmaceuticals after the 1984 Act”. Journal of Law and Economics, 35 (2): 331–350.
13. Henderson, R., and Cockburn, I., 1996. “The Determinants of Research Productivity in Ethical Drug Discovery”. In Competitive Strategies in the Pharmaceutical Industry, Edited by: Helms, R.B., 167–193. Washington, D.C.: American Enterprise Institute Press.
14. Laffont, J-J., and Tirole, J., 1993. A Theory of Incentives in Procurement and Regulation, Cambridge: MIT Press.
15. MacArthur, D., 1997. “Bangemann Round Table: No Break in EU pricing Impasse”. Pharma Pricing Review, 2 (1): 1–6.
16. Pallot, P., 1992. “Fake Drug Fraud: Threat to Patients”. The Daily Telegraph, April 13
17. Phelps, C. 1986. “Cross Subsidies and Charge Shifting in American Hospitals”. In Uncom pensated Medical Care, Edited by: Sloan, F., 108–1255. Baltimore: The Johns Hopins University Press.
18. phRMA (Pharmaceutical REsearch and Manufcturers of America). 1997. Industry Profile.
19. Prieger, J.E., 1996. “Ramsey Pricing and Competition: The Consequences of Myopic Regulation”. Journal of Regulatory Economics, 10: 307–321.
20. Ramsey, F.P., 1927. “A Contribution to the Theory of Taxation”. Economic Journal, 37: 47–61.
21. Rapp, R., and Rozek, R., 1992. “Parallel Trade in Pharmaceuticals: The Impact on Welfare and Innovation”. NERA.
22. Scherer, F.M., 1997. “How US Antitrust Can Go Astray: The Brand Name Prescription Drug Litigation”. International Journal of the Economics of Business, 4 (3): 239–256.
23. Thomas, L.G., 1996. “Industrial Policy and International Competitiveness in the Pharmaceutical Industry”. In Competitive Strategies in the Pharmaceutical Industry, Edited by: Helms, R.B., 107–129. Washington, D.C: American Enterprise Institute Press.
24. Towse, A., “What are the Short and Long Run Implications for the UK of Parallel Trade in Pharmaceuticals?”. 1–20. London: Office of Health Economics. Working Paper
25. Varian, H., 1989. “Price Discrimination”. In Handbook of Industrial Organizations Edited by: Schmalensee, R., and Willig, R